- Home
- SXTC vs ALXO Comparison
SXTC vs ALXO Comparison
Compare SXTC & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SXTC
- ALXO
- Stock Information
- Founded
- SXTC 2005
- ALXO 2015
- Country
- SXTC China
- ALXO United States
- Employees
- SXTC N/A
- ALXO N/A
- Industry
- SXTC Biotechnology: Pharmaceutical Preparations
- ALXO Biotechnology: Pharmaceutical Preparations
- Sector
- SXTC Health Care
- ALXO Health Care
- Exchange
- SXTC Nasdaq
- ALXO Nasdaq
- Market Cap
- SXTC 25.5M
- ALXO 24.0M
- IPO Year
- SXTC 2019
- ALXO 2020
- Fundamental
- Price
- SXTC $1.32
- ALXO $0.56
- Analyst Decision
- SXTC
- ALXO Strong Buy
- Analyst Count
- SXTC 0
- ALXO 6
- Target Price
- SXTC N/A
- ALXO $3.30
- AVG Volume (30 Days)
- SXTC 2.4M
- ALXO 456.6K
- Earning Date
- SXTC 01-01-0001
- ALXO 05-08-2025
- Dividend Yield
- SXTC N/A
- ALXO N/A
- EPS Growth
- SXTC N/A
- ALXO N/A
- EPS
- SXTC 20.77
- ALXO N/A
- Revenue
- SXTC $1,818,404.00
- ALXO N/A
- Revenue This Year
- SXTC N/A
- ALXO N/A
- Revenue Next Year
- SXTC N/A
- ALXO N/A
- P/E Ratio
- SXTC $0.07
- ALXO N/A
- Revenue Growth
- SXTC 6.78
- ALXO N/A
- 52 Week Low
- SXTC $0.95
- ALXO $0.41
- 52 Week High
- SXTC $11.92
- ALXO $10.97
- Technical
- Relative Strength Index (RSI)
- SXTC 41.43
- ALXO 59.08
- Support Level
- SXTC $1.34
- ALXO $0.44
- Resistance Level
- SXTC $1.76
- ALXO $0.48
- Average True Range (ATR)
- SXTC 0.23
- ALXO 0.05
- MACD
- SXTC -0.01
- ALXO 0.02
- Stochastic Oscillator
- SXTC 15.71
- ALXO 99.16
About SXTC China SXT Pharmaceuticals Inc.
China SXT Pharmaceuticals Inc is a pharmaceutical company that is focused on the research, development, manufacture, marketing, and sales of Traditional Chinese Medicine Pieces (TCMP), particularly, TCMP (Directed-oral TCMP, and After-soaking TCMP) which is a sort of Traditional Chinese Medicine (TCM) that has been processed to be ready for use without decoction. Geographically, the firm generates its revenue from the People's Republic of China.
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.